Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more About one in three Americans, or 125 ...
After getting the green light from the FDA back in March, Dexcom today launched its first over-the-counter wearable continuous glucose biosensor, Stelo, in the U.S. market. The device is now available ...
Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) -Dexcom said on Monday its over-the-counter continuous glucose monitor, Stelo, is now available for use in the United ...
The device is similar to existing prescription CGMs. Users pair the wearable sensor with an application, put it on their arm and receive a continuous stream of glucose data on their smartphone or ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...
Tuesday, the FDA approved DexCom Inc’s (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM). The Dexcom Stelo Glucose Biosensor System is ...
The FDA has cleared its first over-the-counter wearable blood sugar tracker, with Dexcom’s slimmed-down Stelo continuous glucose monitor. The agency’s green light allows adults 18 years and older who ...
Dexcom on Monday announced its new over-the-counter continuous glucose monitor Stelo is officially available for purchase in the U.S. Glucose is a type of sugar people receive from food, and it's the ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom ...
DexCom posted better-than-expected Q1 2026 results, with revenue up 15% year-over-year on strong uptake of its G7 continuous glucose monitor and expanded coverage for type 2 diabetes patients not ...
While GLP-1 agonists have grabbed investor attention for their potential as weight loss aids, these medicines also form a ...